Myriad answers the most pressing questions for patients and their healthcare providers.
Because we believe every patient should be able to know their risk, their path, their plan and their choices regarding disease.
Variant Classification
Myriad is the unquestioned industry leader in variant classification and reclassification. myVision™ is the most advanced program in the industry overseeing the classification and reclassification of uncertain variants and is part of Myriad’s commitment to patients and their families.
Affordability
If there is any concern about affordability – no need to worry, we’ve secured great insurance coverage and have very accessible financial assistance programs in place to address your patient’s individual needs.
Advancing the Science
Myriad is dedicated, above all else, to improving patient care through pioneering research and the development of innovative molecular diagnostic tests.
Patient Support & Testing
Myriad is always working to advance the science of biotechnology through our patnerships and professional collaborations
Variant Classification
At Myriad, we employ various methods for variant interpretation in hereditary cancer testing to ensure analytical and interpretive accuracy are ever present, driving the best possible treatment and outcomes.
10,071
Variants Classified in 2016
529
Variants Re-classified in 2016
23,337
Amended Reports Issued in 2016
Affordability
If your patient will be responsible for any non-covered service, we will call them and work with them directly.
We’ve secured great insurance coverage and have very accessible financial assistance programs in place to address your patient’s individual needs.
Lastly, Myriad promises to partner with patients if they encounter ANY financial hardship associated with their bill, and to work with them toward their complete satisfaction.
BROAD INSURANCE COVERAGE
97% of private insurance companies are contracted with Myriad. As a result, the average out-of-pocket bill for patients tested at Myriad is $54, and 3 out of 4 patients have no out-of-pocket expense for their testing.
MYRIAD FINANCIAL ASSISTANCE PROGRAMS
If your patients have high deductible plans or high co-insurance, they may qualify for an out-of-pocket cost of no more than $100.
EXPLANATION OF BENEFITS
EOBs shouldn’t be a concern as they do not represent an amount due to Myriad, but we encourage patients to give us a call if they have any questions about their EOB.
Patient Support & Testing
The Myriad Pledge: Myriad has supported and continues to support research institutions in the advancement of scientific and technological knowledge, and we will not impede noncommercial, academic research that uses patented technology licensed or owned by us.
#1
with in-network providers – 95% of payers with Myriad are in-network
#1
In hereditary cancer tests performed – more than 2.5 million with unmatched reputation for quality
$79.5 Million
Amount provided to support patient advocacy groups over the past 5 years for patient financial assistance and academic scholarships
Advancing the Science
Since 1991, Myriad has invested more than $1 billion to enhance the world’s collective scientific understanding of disease through collaborative research, outreach and education and to translate that knowledge into molecular and companion diagnostic tools that save and improve the lives of the patients we serve.
487
Scientific publications consisting of clinically meaningful information have been published in peer reviewed journals over the past 5 years
$341.7 Million
Invested in research over the past 5 years
57
Academic institutions have collaborated with Myriad to help advance medical and scientific knowledge and healthcare overall. You can view a list of these institutions here.